Choay J. Biologic studies on chemically synthesized penta- saccharide and tetrasaccharide fragments. Semin Thromb Hemost. 1985;11(2):81-85. 195. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. Contribution of 3-O- and 6-O-sulfated glucosamine residues in the heparin-induced conformational change in antithrombin III. Biochemistry. 1987;26(20):6454-6461. 196. Depasse F, Gilbert M, Goret V, Rolland N, Samama MM. Anti-Xamonitoring:inter-assayvariability.ThrombHaemost. 2000;84(6):1122-1123. 197. Kitchen S, Iampietro R, Woolley AM, Preston FE. Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. Thromb Haemost. 1999;82(4):1289-1293. 198. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/ Org31540) with high af nity to antithrombin III in man. Thromb Haemost. 1995;74(6):1468-1473. 199. Donat F, Duret JP, Santoni A, et al. The pharmacoki- netics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002;41(suppl 2):1-9. 200. Lieu C, Shi J, Donat F, et al. Fondaparinux sodium is not metabolised in mammalian liver fractions and does not inhibit cytochrome P450-mediated metabolism of con- comitant drugs. Clin Pharmacokinet. 2002;41(suppl 2): 19-26. 201. Paolucci F, Clavi s MC, Donat F, Necciari J. Fondaparinux sodium mechanism of action: identi cation of speci c binding to puri ed and human plasma-derived proteins. Clin Pharmacokinet. 2002;41(suppl 2):11-18. 202. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation. 2002;106(20):2550-2554. 203. Savi P, Chong BH, Greinacher A, et al. Effect of fonda- parinux on platelet activation in the presence of heparin- dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood. 2005;105(1): 139-144. 204. Rota E, Bazzan M, Fantino G. Fondaparinux-related throm- bocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT). Thromb Haemost. 2008;99(4):779-781. 